**CE Program Announcement: ASHP Alabama Residency Conference 2023**

**April 6, 2023, 12 Noon CDT**

Alabama Society of Health-System Pharmacists is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.  Participants must pre-register, participate in the entire presentation, and complete the online course evaluation to receive continuing pharmacy education credit. Proof of participation will be posted to your NABP CPE profile within 60 days for participants who have successfully completed all requirements. There is [no fee] for ALSHP members to participate in this activity. Non-members fee: $25, which is refundable when joining ALSHP within 30 days of the program date. Participants in this activity are subject to the [Terms and Conditions](https://alshp.wildapricot.org/resources/Documents/ALSHP%20Meetings%20and%20Events%20Terms%20and%20Conditions%203-24-2022%20v1.pdf) for ALSHP meetings and events. Contact mail@alshp.org for questions about this CPE activity. These knowledge-based activities are intended for pharmacists.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Session Number/ Time | Presenters | At the completion of these activities, the participants will be able to: | CE Credit, Contact hours | UAN |
| **1-1** 12:00 | Savannah Jones, PharmDLindsay Allison, PharmDGracelyn Wade, PharmDCharles Hartley, PharmD | * Understand the potential drug interactions associated with melatonin.
* Discuss the changes in antibiotic regimens in patients diagnosed with staphylococcal scalded skin syndrome at Children's of Alabama in the past 10 years.
* Discuss the effects of implementing a standardized vitamin D repletion protocol in the renal transplant population
* Recommend an appropriate treatment option for UTIs caused by vancomycin-resistant enterococci (VRE)
 | 1  | **0172-0000-23-005-L01-P** |
| **1-2**13:05 | Makayla Garcia, PharmDCate Ankersen, PharmDAmanda Sweat, PharmDLinda Tran, PharmD | * Evaluate current medication reconciliation process by nursing and pharmacy. Data will be used to identify areas where additional resources are needed.
* Understand the role of oncology pharmacy specialists.
* Discuss and evaluate the safety and efficacy of once-daily versus twice-daily insulin glargine in acutely ill medical patients and to identify patient characteristics associated with once-daily versus twice-daily dosing.
* Recognize risk factors identified more frequently in patients with methicillin-resistant Staphylococcus aureus community-acquired pneumonia.
 | 1 | **0172-0000-23-006-L01-P** |
| **1-3**14:15 | Brianna Gray, PharmDAshlee Milam, PharmDEmilee Howard, PharmDJay Pitt, PharmD | * Evaluate the impact of the addition of milrinone to iNO for the treatment of Persistent Pulmonary Hypertension of the Newborn.
* Discuss current practices in management of sepsis in the emergency department within a community hospital.
* Evaluate the number of eligible trauma patients who received tranexamic acid prior to the massive transfusion protocol revision and following the revision.
* Evaluate the impact of selected patient characteristics on the primary and secondary outcomes in patients treated with DOACs vs. warfarin.
 | 1 | **0172-0000-23-007-L01-P** |
| **1-4**15:25 | Kreg Montgomery, PharmDTrey Willoughby, PharmDKaitlynn Krupp, PharmDSydney Bowman, PharmD | * Describe the difference in morphine milligram equivalents (MME) between established methadone and morphine weaning protocols for neonates being treated for neonatal abstinence syndrome.
* Evaluate the frequency of vancomycin target AUC using Bayesian modeling in the obese population.
* Describe the differences in Anti-Xa and activated partial thromboplastin time (aPTT) levels when used for heparin monitoring.
* Evaluate the impact of pharmacists on the frequency of appropriate dosing of ketamine and propofol for procedural sedations in the emergency department.
 | 1 | **0172-0000-23-008-L01-P** |
| **2-1**12:00 | Michael Miller, PharmDKyle Humphries, PharmDLauren Cummins, PharmDClay Hayes, PharmD | * Identify the benefits of using extended infusions when dosing cefepime and meropenem to treat gram negative bacterial infections.
* Explain how calcium supplementation during trauma resuscitation at UAB fits with published literature on the topic.
* Explain basic concepts related to the new M100:ED32 breakpoints for piperacillin-tazobactam, and its implications on patient care.
* Assess the difference in post-operative pain control among patients who received an opioid-based pain regimen and those who received an opioid-sparing pain regimen following renal transplantation.
 | 1 | **0172-0000-23-009-L01-P** |
| **2-2**13:05 | Andrew Revels, PharmDChristian Hardrick, PharmDGregory Taylor, PharmDQuinn Hattaway, PharmD | * Describe the impact of rapid molecular blood culture testing on time to initiation of effective antibiotic therapy compared to traditional culture and susceptibility testing.
* Define the efficacy and safety of twice daily versus three times daily dosing of subcutaneous heparin.
* Define the role of hyperoncotic albumin for deresuscitation in volume-overloaded, critically-ill patients with hypoalbuminemia.
* Describe the efficacy and safety of direct oral anticoagulants or the treatment of venous thromboembolism in patients with obesity.
 | 1 | **0172-0000-23-010-L01-P** |
| **2-3**14:15 | Marissa Brakefield, PharmDAmanda Holder, PharmDSahil Patel, PharmDRobert Tooma, PharmD | * Describe the purpose of monitoring serum valproic acid levels.
* Evaluate the current state of vitamin B12 monitoring in patients with Type-2 Diabetes Mellitus (T2DM) who are on metformin therapy, and then perform a pharmacist-driven intervention and assess the impact on the frequency of this monitoring.
* Identify any clinical significant difference between buprenorphine/naloxone and buprenorphine injections when prescribed for opioid use disorder at the Tuscaloosa Veterans Affairs Medical Center.
* Identify patients who are on unwarranted aspirin therapy with a DOAC and use this information to educate providers on guideline recommended use of aspirin and de-escalation.
 | 1 | **0172-0000-23-011-L01-P** |
| **2-4**15:25 | John David Abrams, PharmDJanet “Lindsey” Pitt, PharmDMadissen Humphries, PharmDTurner Huddleston, PharmDAlyssa Krug, PharmD | * Apply evidence-based recommendations for the management of vaso-occlusive crisis (VOC) and acute chest syndrome (ACS) in patients with sickle cell disease.
* Evaluate the appropriateness of HIT antibody test orders and apply evidence based Heparin Induced Thrombocytopenia management.
* Construct appropriate pharmacist interventions to appropriately manage a critically ill patient􀂶s analgesia and sedation regimen.
* Describe the impact of pharmacy involvement in the Centers for Medicare and Medicaid Services' (CMS) sepsis bundle compliance.
* Describe the overall rate of de-escalation from broad spectrum antibiotics and characterize any trends in antibiotic usage in patients with urinary tract infections.
 | 1.25 | **0172-0000-23-012-L01-P** |
| **3-1**12:00 | Leah Winchester, PharmDShelby Buller, PharmDAbigail Switzer, PharmDSara Tyler, PharmD | * Identify appropriate patients for implementation of empagliflozin to decrease cardiovascular risk, improve diabetes, decrease heart-failure related hospitalizations and slow renal function decline.
* Identify benefits associated with symptom-triggered benzodiazepine dosing strategies when compared to scheduled benzodiazepine administration.
* Evaluate the safety of vancomycin use and identify the need for transition to AUC/MIC based dosing.
* Identify patient-specific factors that can increase a patient’s risk for hypoglycemia.
 | 1 | **0172-0000-23-013-L01-P** |
| **3-2**13:05 | Adriane York, PharmDJennifer Ha, PharmDLacey Hughes, PharmDCecilia Hughes, PharmD | * Evaluate the impact of utilizing continuous glucose monitoring devices on financial and clinical outcomes in a family medicine clinic.
* Compare the hemoglobin A1c lowering ability of insulin glargine and insulin glargine-yfgn.
* Describe the impact that pharmacist-driven inhaler education has on symptom management for COPD.
* Discuss the difference in adherence rates to Star measure anti-diabetic agents in VIVA MEDICARE members living in highly rural vs. urban counties as defined by the Alabama Rural Health Association
 | 1 | **0172-0000-23-014-L01-P** |
| **3-3**14:15 | Morgan Rambo, PharmDRachel Buchanan, PharmDVictoria Donaldson, PharmDBrandon Duplantis, PharmD | * Describe the impact of early pharmacist intervention on readmission rates in a high-risk heart failure population

identified through a nationally published dashboard.* Describe recent trends of outpatient antibiotic usage and assess complication rates of IV antibiotic therapy.
* Describe the impact of using an updated nursing template for 2-Day Post-Discharge Calls that prompts consultation of other providers and assess how that affects continuity of patient care.
* Describe the effectiveness of academic detailing on pharmacogenomic testing ordering by clinicians at a Veterans Affairs Health Care System.
 | 1 | **0172-0000-23-015-L01-P** |
| **3-4**15:25 | Tyler Mitchell, PharmDRobyn Best, PharmDWilliam Carleton, PharmDJames Miracle, PharmDAnna-Kathryn Priest, PharmD | * Describe the outcomes of adding positive Clostridioides difficile results to the physician notification protocol at a community hospital.
* Discuss the appropriate utilization of famotidine for stress ulcer prophylaxis (SUP).
* Identify the difference between time on mechanical ventilation when vecuronium is administered as a continuous infusion or an intermittent push in patients with acute respiratory distress syndrome (ARDS).
* Describe the role of the ED pharmacist with respect to outpatient urine culture follow-up.
* Describe the role of the emergency department pharmacist with respect to outpatient blood culture follow-up.
 | 1.25 | **0172-0000-23-016-L01-P** |